Express Scripts Holding Co (ESRX)

ESRX (NASDAQ:Health Services) EQUITY
$85.41
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | ESRX Avg Daily Volume: 3,651,200
Last Update: 03/30/15 - 4:00 PM EDT
Volume: 0
YTD Performance: 0.87%
Open: $0.00
Previous Close: $85.41
52 Week Range: $64.64 - $88.83
Oustanding Shares: 726,898,000
Market Cap: 60,037,957,702
6-Month Chart
TheStreet Ratings Grade for ESRX
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 11 12 12
Moderate Buy 3 3 3 3
Hold 6 6 5 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.73 1.73 1.63 1.55
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 31.20
Price Earnings Comparisons:
ESRX Sector Avg. S&P 500
31.20 31.20 27.35
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-0.40% 13.09% 57.63%
GROWTH 12 Mo 3 Yr CAGR
Revenue -3.10 1.19 0.29
Net Income 8.70 0.60 0.17
EPS 17.90 0.05 0.02
Earnings for ESRX:
EBITDA 5.85B
Revenue 100.89B
Average Earnings Estimates
Qtr (03/15) Qtr (06/15) FY (12/15) FY (12/16)
Average Estimate $1.10 $1.36 $5.44 $6.02
Number of Analysts 14 13 17 16
High Estimate $1.14 $1.39 $5.49 $6.15
Low Estimate $1.08 $1.32 $5.37 $5.92
Prior Year $0.99 $1.23 $4.88 $5.44
Growth Rate (Year over Year) 11.18% 10.82% 11.38% 10.76%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands

updateESRX Investor Mtg.

Feb 25, 2015 | 6:55 AM EST

ESRX - Express Scripts Holding Co Investor Meeting - 8:30AM St. Louis, MO

By

Jim Cramer

 | Feb 19, 2015 | 11:02 AM EST

Watch this leadership group that's been lagging.

bearishExpress Scripts downgraded at FBR

Jan 28, 2015 | 6:42 AM EST

ESRX was downgraded from Outperform to Market Perform, FBR Capital Markets said. Valuation call, as the company lacks near-term catalysts.

 

By

Bret Jensen

 | Jan 6, 2015 | 10:30 AM EST

They offer a nice shelter for the headwinds now hitting equities.

By

Chris Laudani

 | Dec 30, 2014 | 11:00 AM EST

Its hepatitis C drug will dominate the market.

By

David Katz

 | Dec 26, 2014 | 12:30 PM EST

Its hepatitis C drug is better; the stock trades at a discount.

By

Jim Cramer

 | Dec 23, 2014 | 2:36 PM EST

Here's the best way to play them.

By

Jim Cramer

 | Dec 23, 2014 | 1:11 PM EST

Stocks that do well when the economy rises are shining.

By

Bret Jensen

 | Dec 23, 2014 | 12:00 PM EST

It has a great long-term future.

By

Jim Cramer

 | Dec 22, 2014 | 1:12 PM EST

It might be good for consumers, but not for the stock.

Early yesterday I spoke here about the position we had on RH, and late in the day we sold ...
Exxon Mobil (XOM) shares are back up near the $85.75 level. This area was solid support fo...
Good closing piece by "El Capitan" on the nature of buyers these days. I totally agree. As...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.